Clinical trials: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
The objective of this early access program (EAP) is to provide access to tofersen to eligible participants with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene prior to an…
- Trial name
- NCT04972487
- Testing
- Tofersen
- Where
- 19 sites in United States
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as…
- Trial name
- NCT07223723
- Testing
- Tofersen
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms
In this study, researchers will learn more about the effects of a drug called tofersen, also known as BIIB067 and QALSODY®, in adults with amyotrophic lateral sclerosis (ALS) who have a superoxide dismutase 1 (SOD1) gene…
- Trial name
- ATLAS (NCT04856982)
- Testing
- Tofersen
- Where
- 32 sites in United States, Australia and 12 more
- Volunteers
- 158 people
- Sponsor
- Biogen